全部集團訊息
-
UBI/聯亞集團提出高精準設計COVID-19新冠疫苗UB-612第二期臨床試驗申請
UBI/聯亞集團提出高精準設計COVID-19新冠疫苗UB-612第二期臨床試驗申請UBI/聯亞集團提出高精準設計COVID-19新冠疫苗UB-612第二期臨床試驗申請more -
United BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital Herpes
United BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital HerpesUnited BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital Herpesmore -
全人單株抗體UB-621用於復發性生殖器皰疹病患2期臨床試驗獲中國NMPA核准執行
全人單株抗體UB-621用於復發性生殖器皰疹病患2期臨床試驗獲中國NMPA核准執行全人單株抗體UB-621用於復發性生殖器皰疹病患2期臨床試驗獲中國NMPA核准執行more -
COVAXX Initiates Phase 1 Clinical Trial of COVID-19 Vaccine UB-612 in Taiwan
COVAXX Initiates Phase 1 Clinical Trial of COVID-19 Vaccine UB-612 in TaiwanCOVAXX Initiates Phase 1 Clinical Trial of COVID-19 Vaccine UB-612 in Taiwanmore -
UBI/聯亞集團所研發之高精準設計COVID-19疫苗UB-612第一期臨床試驗計畫獲台灣衛福部同意施打受試者
UBI/聯亞集團所研發之高精準設計COVID-19疫苗UB-612第一期臨床試驗計畫獲台灣衛福部同意施打受試者UBI/聯亞集團所研發之高精準設計COVID-19疫苗UB-612第一期臨床試驗計畫獲台灣衛福部同意施打受試者more -
Beyond the Spike: The COVAXX Approach to a COVID-19 Vaccine
Beyond the Spike: The COVAXX Approach to a COVID-19 VaccineBeyond the Spike: The COVAXX Approach to a COVID-19 Vaccinemore -
The Most Powerful Vaccine You’ve Never Heard Of | Tony Robbins + Peter Diamandis Webinar
The Most Powerful Vaccine You’ve Never Heard Of | Tony Robbins + Peter Diamandis WebinarThe Most Powerful Vaccine You’ve Never Heard Of | Tony Robbins + Peter Diamandis Webinarmore -
UBI/聯亞集團所研發之高精準設計COVID-19疫苗UB-612獲台灣衛福部有條件核准進行第一期臨床試驗
UBI/聯亞集團所研發之高精準設計COVID-19疫苗UB-612獲台灣衛福部有條件核准進行第一期臨床試驗UBI/聯亞集團所研發之高精準設計COVID-19疫苗UB-612獲台灣衛福部有條件核准進行第一期臨床試驗more -
United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infectionUnited BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infectionmore -
聯生藥抗體新藥UB-421用於多重抗藥性愛滋病患3期臨床試驗獲中國NMPA核准執行
聯生藥抗體新藥UB-421用於多重抗藥性愛滋病患3期臨床試驗獲中國NMPA核准執行聯生藥抗體新藥UB-421用於多重抗藥性愛滋病患3期臨床試驗獲中國NMPA核准執行more -
聯生藥抗體新藥UB-421皮下注射(SC)劑型 獲台灣衛福部核准進行臨床I期試驗
聯生藥抗體新藥UB-421皮下注射(SC)劑型 獲台灣衛福部核准進行臨床I期試驗聯生藥抗體新藥UB-421皮下注射(SC)劑型 獲台灣衛福部核准進行臨床I期試驗more
